Abstract
Llovet et al. (July 24 issue)1 report that their study of sorafenib therapy in patients with hepatocellular carcinoma showed a higher overall incidence of treatment-related adverse events with sorafenib than with placebo (80% vs. 52%), although the difference was not noted to be significant. The availability of new therapies, with expected small variations in objective end points, has heightened awareness of the importance of the impact of treatment on patients' overall lives.2 Besides the traditional end points (e.g., median overall survival and time to radiologic progression), quality of life has been acknowledged as an important issue in cancer clinical trials and clinical practice.3,4 We think that an assessment of patients' quality of life would have provided important complementary information to be evaluated in the article.

This publication has 15 references indexed in Scilit: